The emergency caused by Covid-19 pandemic raised interest in studying lifestyles and comorbidities as important determinants of poor Covid-19 prognosis. Data on tobacco smoking, alcohol consumption and obesity are still limited, while no data are available on the role of e-cigarettes and heated tobacco products (HTP). To clarify the role of tobacco smoking and other lifestyle habits on COVID-19 severity and progression, we designed a longitudinal observational study titled COvid19 and SMOking in ITaly (COSMO-IT). About 30 Italian hospitals in North, Centre and South of Italy joined the study. Its main aims are: 1) to quantify the role of tobacco smoking and smoking cessation on the severity and progression of COVID-19 in hospitalized patients; 2) to compare smoking prevalence and severity of the disease in relation to smoking in hospitalized COVID-19 patients versus patients treated at home; 3) to quantify the association between other lifestyle factors, such as e-cigarette and HTP use, alcohol and obesity and the risk of unfavourable COVID-19 outcomes. Socio-demographic, lifestyle and medical history information will be gathered for around 3000 hospitalized and 700-1000 home-isolated, laboratory-confirmed, COVID-19 patients. Given the current absence of a vaccine against SARS-COV-2 and the lack of a specific treatment for COVID-19, prevention strategies are of extreme importance. This project, designed to highly contribute to the international scientific debate on the role of avoidable lifestyle habits on COVID-19 severity, will provide valuable epidemiological data in order to support important recommendations to prevent COVID-19 incidence, progression and mortality.
Covid-19 and the role of smoking: The protocol of the multicentric prospective study COSMO-IT (covid19 and smoking in italy) / Cattaruzza, M. S.; Gorini, G.; Bosetti, C.; Boffi, R.; Lugo, A.; Veronese, C.; Carreras, G.; Santucci, C.; Stival, C.; Pacifici, R.; Zaga, V.; Gallus, S.; Giulietti, F.; Sarzani, R.; Spannella, F.; Del Donno, M.; Tartaglione, S.; Marrazzo, G.; Pelaia, G.; D'Agosto, V.; Berti, A.; Voller, F.; Cardellicchio, S.; Cresci, C.; Foschino Barbaro, M. P.; De Palma, R.; Negrini, S.; Sicbaldi, V.; Serafini, A.; Bisconti, M.; Refolo, L.; Landoni, G.; Rovere, P.; Veronesi, G.; Faverio, P.; Garavello, W.; Pesci, A.; Giacobbe, R.; Martucci, P.; Parrella, R.; Scarano, F.; Aiello, M.; Chetta, A.; Franco, C.; Mangia, A.; Carrozzi, L.; Maggi Monzani, F. F.; Pistelli, F.; Russo, P.; Sanna, A.; Barreca, F. M.; Conti, V.; Rossi, E.; Ruli, M.; Ruli, S.; Varzaneh, S. E.; Principe, R.; Guerrini, S.; Sebastiani, A.; Galluccio, G.; Pezzuto, A.; Ricci, A.; Casali, E.; Mastroianni, C.; Pirina, P.; Polo, F.; Zaga, V.; Beatrice, F.; Romagnoli, M.; Baraldo, M.; Cojutti, P. G.; Graziano, E.; Pecori, D.; Tascini, C.; Tinghino, B.. - In: ACTA BIO-MEDICA DE L'ATENEO PARMENSE. - ISSN 0392-4203. - 91:3(2020), pp. 1-6. [10.23750/abm.v91i3.10373]
Covid-19 and the role of smoking: The protocol of the multicentric prospective study COSMO-IT (covid19 and smoking in italy)
Aiello M.;Chetta A.;Mangia A.;
2020-01-01
Abstract
The emergency caused by Covid-19 pandemic raised interest in studying lifestyles and comorbidities as important determinants of poor Covid-19 prognosis. Data on tobacco smoking, alcohol consumption and obesity are still limited, while no data are available on the role of e-cigarettes and heated tobacco products (HTP). To clarify the role of tobacco smoking and other lifestyle habits on COVID-19 severity and progression, we designed a longitudinal observational study titled COvid19 and SMOking in ITaly (COSMO-IT). About 30 Italian hospitals in North, Centre and South of Italy joined the study. Its main aims are: 1) to quantify the role of tobacco smoking and smoking cessation on the severity and progression of COVID-19 in hospitalized patients; 2) to compare smoking prevalence and severity of the disease in relation to smoking in hospitalized COVID-19 patients versus patients treated at home; 3) to quantify the association between other lifestyle factors, such as e-cigarette and HTP use, alcohol and obesity and the risk of unfavourable COVID-19 outcomes. Socio-demographic, lifestyle and medical history information will be gathered for around 3000 hospitalized and 700-1000 home-isolated, laboratory-confirmed, COVID-19 patients. Given the current absence of a vaccine against SARS-COV-2 and the lack of a specific treatment for COVID-19, prevention strategies are of extreme importance. This project, designed to highly contribute to the international scientific debate on the role of avoidable lifestyle habits on COVID-19 severity, will provide valuable epidemiological data in order to support important recommendations to prevent COVID-19 incidence, progression and mortality.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
